It was demonstrated that MFAP4 deficiency inhibits cardiac fibrosis and ventricular arrhythmias in mice models and therefore may act as a novel therapeutic target for the prevention of cardiac remodeling in HF (49). This evidence concerns the gene MFAP4 and Ventricular arrhythmia.